VCB-1102

N/A

Report date: 2025/06/30 17:21:53

Base Information

Drug NameVCB-1102
Drug Alias NameVCB-1102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSmall Cell Lung CarcinomaLiver NeoplasmsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVaxcellBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesVaxcellBio Inc
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaLiver NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A